Document:

Exhibit

Exhibit 10.2

AMENDMENT NO. 2
TO THE SUPPLY AGREEMENT

THIS AMENDMENT NO. 2 (“Amendment No. 2”), TO THE Supply Agreement is entered into as of June 18, 2019 by and between Radius Health, Inc. (“Radius”) and Ypsomed AG (“Ypsomed”).

WHEREAS, Radius and Ypsomed are parties to that certain Supply Agreement having an effective date of September 30, 2015 and as amended by a first amendment as of February 7, 2017 (the “Agreement”); and

WHEREAS, pursuant to Section 4.8 of the Agreement, the Parties wish to modify the Agreement to reflect that Radius may purchase, and Ypsomed shall supply, Component Sets for use with abaloparatide finished drug product to be commercialized by Radius or its commercial partner in Canada.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, the Parties agree to amend the Agreement as follows: 
1.The definition of Authority in Section 1 of the Agreement is hereby amended and restated in its entirety as follows:

“ ‘Authority’ shall mean the Food and Drug Administration (“FDA”) in the United States, the Canadian Federal Department known as Health Canada, the European Medicines Agency EMEA in Europe, and/or the applicable equivalent regulatory agency or entity, governmental or non-governmental, having the responsibility, jurisdiction and authority for the grant of Authorizations in any jurisdiction in the Territory.

2.The definition of Territory in Section 1 of the Agreement is hereby amended and restated in its entirety as follows:

“ ‘Territory’ shall mean shall mean the USA, the European Union, Canada and Switzerland. Further countries may be included upon mutual agreement and in accordance with Section 4.8.”

3.For clarity, the Parties agree that Radius or its designees, including its commercialization partners, shall be responsible for the obligations and costs set forth in Section 16.1 of the Agreement.  

4.All other terms and conditions of the Agreement shall remain in full force and effect.  Capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the Agreement.

IN WITNESS WHEREOF, the parties have caused this Amendment No. 2 to be executed by their duly authorized representatives.

[signatures on following page]

		
	RADIUS HEALTH, INC.
	YPSOMED AG

	
					
	By:
	/s/ Chhaya Shah
	 
	By:
	/s/ Frank Schiffmaun

	Name:
	Chhaya Shah
	 
	Name:
	Frank Schiffmaun

	Title:
	SVP, Technical Operations
	 
	Title:
	Senior Director, Ypsomed Delivery Systems

	Date:
	June 10, 2019
	 
	Date:
	June 18, 2019

	 
	 
	 
	By:
	/s/ Ulrike Bauer

	 
	 
	 
	Name:
	Ulrike Bauer

	 
	 
	 
	Title
	SVP, Delivery Systems

2Exhibit

Exhibit 10.3

AMENDMENT NO. 2
TO THE MANUFACTURING SERVICES AGREEMENT

THIS AMENDMENT NO. 2 (“Amendment No. 2”), TO THE Manufacturing Services Agreement is entered into as of June 10, 2019 by and between Radius Health, Inc., (“Radius”) and Lonza Sales Ltd (hereinafter “Lonza” or “PolyPeptide”).

WHEREAS, Radius and PolyPeptide are parties to that certain Manufacturing Services Agreement having an effective date of June 28, 2016, as previously amended by Amendment No. 1 dated December 11, 2018 (the “Agreement”); and

WHEREAS, the Parties wish to modify the Agreement to reflect that Radius may order, and PolyPeptide shall supply, Product for use with abaloparatide finished drug product to be commercialized by Radius or its commercial partner in Canada.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, the Parties agree to amend the Agreement as follows: 

1.All references in the Agreement to Lonza shall hereinafter be deemed amended to refer to PolyPeptide Group (“PolyPeptide”).

2.The definition of Applicable Laws in Section 1 of the Agreement is hereby amended and restated in its entirety as follows: 

“ ‘Applicable Laws’ means all relevant U.S., Canadian, and European Union national/federal, state and local laws, statutes, rules, and regulations which are applicable to a Party’s activities hereunder, including, without limitation, the applicable regulations and guidelines of any Governmental Authority and all applicable cGMP together with amendments thereto and those concerning anti-corruption and anti-bribery.”

3.The definition of cGMP in Section 1 of the Agreement is hereby amended and restated in its entirety as follows:

“ ‘cGMP’ means those laws and regulations applicable in the U.S., Canada and Europe, relating to the manufacture of medicinal products for human use, including, without limitation, current good manufacturing practices as specified in the ICH guidelines, including without limitation, ICH Q7A “ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients”, US Federal Food Drug and Cosmetic Act at 21 CFR (Chapters 210, 211, 600 and 610), the Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 91/356/EEC, and those good manufacturing practices standards required by Health Canada. For the avoidance of doubt, PolyPeptide’s operational quality standards are defined in internal cGMP policy documents.

		
	4.
	Section 1 of the Agreement is amended to add the following definition:

“ ‘Health Canada’ means the Canadian Federal Department known as Health Canada, or any successor agency thereto, and its divisions, including the Therapeutic Products Directorate and the Health Products and Food Branch Inspectorate.”

5.The definition of Regulatory Authority in Section 1 of the Agreement is hereby amended and restated in its entirety as follows:

“ ‘Regulatory Authority’ means the FDA, EMA, Health Canada and any other similar regulatory authorities as may be agreed upon in writing by the Parties.”

6.The Parties agree that regulatory support activities for approval of the Product in Canada requested by Radius shall be performed and supported by PolyPeptide in accordance with the terms and conditions of Section 2.4.2 of the Agreement.  

7.All other terms and conditions of the Agreement shall remain in full force and effect.  Capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the Agreement.

IN WITNESS WHEREOF, the parties have caused this Amendment No. 2 to be executed by their duly authorized representatives.

[signatures on following page]

		
	RADIUS HEALTH, INC.
	POLYPEPTIDE GROUP

	
					
	By:
	/s/ Chhaya Shah
	 
	By:
	/s/ Robert Hagopian

	Name:
	Chhaya Shah
	 
	Name:
	Robert Hagopian

	Title:
	SVP, Technical Operations
	 
	Title:
	Director, Business Development

	Date:
	June 10, 2019
	 
	Date:
	July 25, 2019

2Exhibit

AMENDMENT NO. 7

to

CONSULTING AGREEMENT
dated May 3, 2012

by and between
AXIS Specialty Limited (the “Company”)
and
Michael A. Butt (the “Consultant”)

Dated July 18, 2019

WHEREAS, the Company and the Consultant entered into a consulting agreement dated as of May 3, 2012, as amended (the “Agreement”); and

WHEREAS, the Compensation Committee of the Board of Directors of AXIS Capital Holdings Limited, the Company and the Consultant have determined that it is in the best interests of the Company and its shareholders to make certain revisions to the Agreement in order to further extend the term of service and schedule of payments;

NOW, THEREFORE, the Agreement is hereby amended, effective as of the date hereof, as follows:

		
	1.
	Section 3 of the Agreement (Consulting Fee) is hereby amended to insert the following after “April 2019.”:

“For service from the date of the Annual General Meeting of AXIS Capital Holdings Limited in 2019 through December 31, 2020, the Company shall pay the Consultant a fee in the amount of $500,000 to be payable as follows:

$50,000 due no later than July 30, 2019
$50,000 due no later than October 1, 2019
$100,000 due no later than January 2, 2020
$100,000 due no later than April 1, 2020
$100,000 due no later than July 1, 2020
$100,000 due no later than October 1, 2020”
		
	2.
	Section 4 of the Agreement (Consulting Term) is hereby amended by deleting the reference to “at the Annual General Meeting of AXIS Capital Holdings Limited in 2020” and replacing such reference with “on December 31, 2020”.

		
	3.
	Section 8 of the Agreement (Noncompetition and Nonsolicitation) is hereby amended by deleting the reference to “May 31, 2021” in the last line thereof and replacing such reference with “December 31, 2021”.

		
	4.
	Except as set forth herein, all other terms and conditions of the Agreement shall remain in full force and effect.   

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first written above.

                        
	
	
	AXIS Specialty Limited

	 

	/s/ Peter J. Vogt

	Executive Vice President and Chief Financial Officer

	 

	Consultant

	 

	/s/ Michael A. Butt

	 

	 

2Exhibit

Exhibit 10.1

FIRST AMENDMENT TO 
AMENDED AND RESTATED SHARED SERVICES AGREEMENT 
 

THIS FIRST AMENDMENT TO AMENDED AND RESTATED SHARED SERVICES AGREEMENT (the “Amendment”) effective as of the 1st day of January, 2019, is made and entered into by and between B. F. Saul Company, a corporation organized under the laws of the District of Columbia (“Saul Company”), which definition shall be deemed to include, for purposes of this Amendment, all consolidated subsidiaries of Saul Company), and Saul Centers, Inc., a corporation organized under the laws of the State of Maryland (“Saul Centers,” which definition shall be deemed to include, for purposes of this Amendment, Saul Holdings Limited Partnership and all of its subsidiaries).  Saul Company and Saul Centers shall collectively be referred to herein as the “parties.”
W I T N E S S E T H:
WHEREAS, Saul Company and Saul Centers entered into that certain Amended and Restated Shared Services Agreement effective as of January 1, 2018 (the “Original Agreement”), whereby the parties established certain standards and procedures for sharing costs and services as more particularly set forth in the Original Agreement.
WHEREAS, Saul Company and Saul Centers desire to amend and supplement the terms of the Original Agreement to incorporate an additional category of costs allocated between the parties relating to retail leasing services provided by Saul Centers to Saul Company as more particularly set forth below.
NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows.
AGREEMENT:
		
	1.
	Recitals.  The above recitals are incorporated herein by this reference.

		
	2.
	Capitalized Terms. All capitalized terms used herein but not otherwise defined in this Amendment shall have the same meaning ascribed to such terms in the Original Agreement.  

3.Leasing Costs.
		
	(a)
	Retail Leasing Group. The Retail Leasing Group (the “Retail Leasing Group”) is composed of Employees of Saul Centers.  From time to time, the Retail Leasing Group performs leasing services for Saul Company.    

		
	(b)
	Retail Leasing Group Costs. 

		
	(i)
	Commencing on the date hereof and continuing each year thereafter, Saul Centers shall determine the monthly costs (“Leasing Employee Cost”) 

1

Exhibit 10.1

of each employee in the Retail Leasing Group (individually, a “Leasing Employee” and collectively, the “Leasing Employees”).  The Leasing Employee Cost will be calculated by adding the following and dividing it by twelve (12) months:
		
	(1)
	annual base salary paid by Saul Centers of such Leasing Employee;

		
	(2)
	annual bonus or other financial incentive paid by Saul Centers to the Leasing Employee excluding, however, any leasing commissions paid to any Leasing Employee;

		
	(3)
	annual employer contributions based on the amount of cash compensation such as social security tax and retirement account matching; and

		
	(4)
	other expenses of the home department of the Leasing Employee based on the average cost per person in his or her applicable group, which shall include all rent, office expenses, professional fees, information technology costs, and other related costs and depreciation attributable to the applicable group.

		
	(ii)
	In addition, commencing on the date hereof and continuing each year thereafter, Saul Centers shall also identify all leasing commissions and annual employer contributions based on the amount of cash compensation such as related payroll taxes and retirement account matching contributions incurred as a result of the leasing commission; attributable to Saul Company leases, paid to each Leasing Employee in accordance with the then applicable Leasing Employee commission schedule, as the same may be amended from time to time with notice to Saul Company (collectively, the “Commissions”). 

		
	(c)
	Calculating Payment.  Employees of the Retail Leasing Group will track the actual work hours spent in Saul Company matters.  The parties will determine the percentage of time spent monthly by each Leasing Employee in Saul Company leasing matters and compute the ratio of actual work hours spent in Saul Company matters to the actual hours paid to the Leasing Employee (the “Leasing Monthly Percentage”).  Saul Company agrees to pay to Saul Centers: (i) the Leasing Monthly Percentage of the Leasing Employee Costs for each of the Leasing Employees, and (ii) all of the Commissions (collectively, the “Leasing Group Costs”).  

		
	4.
	Collection Costs.

		
	(a)
	Collection Group.  The Collection Group (the “Collection Group”) is composed of Employees of Saul Centers.  From time to time, the Collection Group performs services for Saul Company.

2

Exhibit 10.1

		
	(b)
	Collection Group Costs. 

Commencing on the date hereof and continuing each year thereafter, Saul Centers shall determine the monthly costs (“Collection Employee Cost”) of each employee in the Collection Group (individually, a “Collection Employee” and collectively, the “Collection Employees”).  The Collection Employee Cost will be calculated by adding the following and dividing it by twelve (12) months:
		
	(1)
	annual base salary paid by Saul Centers of such Collection Employee;

		
	(2)
	annual bonus or other financial incentive paid by Saul Centers to the Collection Employee; 

		
	(3)
	annual employer contributions based on the amount of cash compensation such as social security tax and retirement account matching; and

		
	(4)
	other expenses of the home department of the Collection Employee based on the average cost per person in his or her applicable group, which shall include all rent, office expenses, professional fees, information technology costs, and other related costs and depreciation attributable to the applicable group.

		
	(c)
	Calculating Payment.  Employees of the Collection Group will report the percentage of time historically spent on Saul Company matters (the “Semi-annual Percentage”).  These percentages will be reported, reviewed, and used to update the billing rates on a semi-annual basis, in arrears. Saul Company agrees to pay to Saul Centers on a monthly basis the Semi-annual Percentage of the Collection Employee Costs for each of the Collection Employees (collectively, the “Collection Group Costs”).

		
	5.
	Incorporation of Other Terms; Payment.  All of the provisions of the Original Agreement applicable to costs and services shall apply to the Leasing Group Costs and Collection Group Costs and are incorporated herein by reference.  Without limiting the generality of the foregoing, Section 9(a) of the Original Agreement shall be supplemented to include the Leasing Group Costs and Collection Group Costs as follows:

		
	“(a) 
	Monthly Payment. Each of the parties hereto agrees to pay to the other, on a monthly basis, its allocation of the following costs as calculated pursuant to this Agreement:

		
	(i)
	the Headquarters Shared Costs;

		
	(ii)
	the Auditor Space Costs;

		
	(iii)
	the Support Group Costs;

		
	(iv)
	the Industry Groups Costs;

		
	(v)
	the Company-Wide Shared Costs;

		
	(vi)
	the Shared Program Costs;

		
	(vii)
	the IT Shared Costs;

3

Exhibit 10.1

		
	(viii)
	the Legal Services; 

		
	(ix)
	the Leasing Group Costs; and

		
	(x)
	the Collection Group Costs.  

The parties agree that as an administrative convenience, Saul Centers may offset its monthly payment to Saul Company by the monthly amounts owed to Saul Centers by Saul Company under this Agreement.”
		
	6.
	Ratification of Agreement.    The Original Agreement, as amended and supplemented by this Amendment, is hereby ratified and affirmed by the parties, and shall remain in full force and effect pursuant to its terms as amended hereby.

		
	7.
	Miscellaneous. In the event of any conflict between the terms of this Amendment and the terms of the Original Agreement, the terms of this Amendment shall prevail.

[signature page follows]

4

Exhibit 10.1

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date and year first above written.

B. F. SAUL COMPANY

                    

By: /s/ Patrick T. Connors_________    
Name: Patrick T. Connors
Title: Senior Vice President

SAUL CENTERS, INC.

                    
By: /s/ Scott V. Schneider_________    
Name: Scott V. Schneider
Title: Senior Vice President

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}]]